Plasma Pyrophosphate Imbalance According to Phenotype and Bone Remodelling Alterations in Type 1 Neurofibromatosis - PIRATE-NF1 - (PIRATE)
Neurofibromatosis type 1 (NF1) is a multisystemic genetic disorder associated with frequent tumor, skin, visceral, and bone manifestations. Plexiform neurofibromas (PFNs), whether superficial or deep, affect 20 to 50 percent of patients and are responsible for significant morbidity. Inoperable, symptomatic PFNs can now be treated with targeted therapy (selumetinib) in both children and adults. Furthermore, NF1 patients frequently present with bone abnormalities, such as bone dysplasia, scoliosis, or reduced bone mineral density, suggesting impaired mineralization.
Inorganic pyrophosphate (PPi) is a potent antagonist of bone mineralization. It has been shown in a mouse model of NF1 and in human Schwann cell cultures derived from patients with NF1 (2 cases) that there is activation of genes regulating PPi homeostasis, particularly ANKH and ENPP1.
This study aims to measure plasma PPi levels in a cohort of patients with NF1 from the general population, based on their phenotype-specifically, the presence, location, and characteristics of NFPs-as well as their calcium and phosphorus levels.
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Issam BILAL, MS
- Phone Number: +330241356828
- Email: Issam.Bilal@chu-angers.fr
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
40 patients. Age ≥18 years ; Confirmed diagnosis of NF1, based on current clinical and/or molecular criteria.
Description
Inclusion Criteria:
- Age ≥18 years
- Confirmed diagnosis of NF1, based on current clinical and/or molecular criteria
- Consent obtained
Exclusion Criteria:
- Other condition affecting bone mineralization
- Known severe renal insufficiency
- Patient who refuses to participate in the study
Study Plan
How is the study designed?
Design Details
- Observational Models: COHORT
- Time Perspectives: PROSPECTIVE
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Diagnosed patients with NF1
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
PPi plasma concentration.
Time Frame: Visite 1
|
Visite 1
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Plasma PPI Levels in NF1 patients
Time Frame: At the time of the consultation
|
At the time of the consultation
|
|
|
Urine PPI Levels in NF1 patients
Time Frame: At the time of the consultation
|
At the time of the consultation
|
|
|
presence of a plexiform neurofibroma in NF1 patients
Time Frame: At the time of the consultation
|
At the time of the consultation
|
|
|
presence of bone abnormalities in NF1 patients
Time Frame: At the time of the consultation
|
At the time of the consultation
|
|
|
Urinary PPI measurement in newly diagnosed patients with NF1
Time Frame: At the time of the consultation
|
At the time of the consultation
|
|
|
Location of plexiform neurofibromas
Time Frame: At the time of the consultation
|
At the time of the consultation
|
|
|
Calcium measurement
Time Frame: At the time of the consultation
|
Biological parameters of calcium-phosphorus metabolism (calcium, phosphorus, vitamin D, and PTH) |
At the time of the consultation
|
|
Phosporus measurement
Time Frame: At the time of the consultation
|
Biological parameters of calcium-phosphorus metabolism (calcium, phosphorus, vitamin D, and PTH) |
At the time of the consultation
|
|
Vitamine D Assay
Time Frame: At the time of the consultation
|
Biological parameters of calcium-phosphorus metabolism (calcium, phosphorus, vitamin D, and PTH) |
At the time of the consultation
|
|
Parathyroid hormone (PTH) measurement
Time Frame: At the time of the consultation
|
Biological parameters of calcium-phosphorus metabolism (calcium, phosphorus, vitamin D, and PTH) |
At the time of the consultation
|
|
Treatment with selumetinib
Time Frame: Visite 1
|
Visite 1
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Pauline BOITEZ, MD, University Hospital, Angers
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nervous System Diseases
- Neoplasms
- Neuromuscular Diseases
- Genetic Diseases, Inborn
- Peripheral Nervous System Diseases
- Neoplasms by Histologic Type
- Neurodegenerative Diseases
- Neoplasms, Nerve Tissue
- Nervous System Neoplasms
- Heredodegenerative Disorders, Nervous System
- Nerve Sheath Neoplasms
- Neoplastic Syndromes, Hereditary
- Neurocutaneous Syndromes
- Peripheral Nervous System Neoplasms
- Neurofibroma
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities
- Neurofibromatoses
- Neurofibromatosis 1
- Neurofibroma, Plexiform
Other Study ID Numbers
Other Study ID Numbers
- 49RC26_0384
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.